Agendia Establishes Contract with Humana To Cover MammaPrint - Gilde Healthcare

Agendia Establishes Contract with Humana To Cover MammaPrint

October 19, 2010

IRVINE, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company’s MammaPrint test.  Agendia’s contract with Humana expands the coverage for MammaPrint by more than 17 million lives.  In November 2009, Palmetto GBA, California’s Part B Medicare administrator, established coding guidelines for MammaPrint, allowing healthcare providers from across the United States to submit claims for the test.  MammaPrint is the first and only FDA-cleared breast cancer recurrence test available and has been reimbursed by payors since 2008.

“Humana is dedicated to advancing excellence in healthcare delivery on behalf of its members.  This commitment to quality care and patient safety has now led Humana to include MammaPrint in its medical benefit management program,”

said Bernhard Sixt, Chief Executive Officer of Agendia.

“We are proud that Humana is offering its members coverage for the only gene expression test for breast cancer recurrence which has been cleared by the FDA.”

Humana, headquartered in Louisville, Kentucky, is one of the nation’s largest publicly traded health and supplemental benefits companies, with approximately 10.4 million medical members and approximately 7.2 million specialty-benefit members.  Humana is a full-service benefits-solutions company, offering a wide array of health and supplementary benefit plans for employer groups, government programs and individuals.

About MammaPrint®

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed.  Highly accurate, MammaPrint identifies patients with early metastasis risk — patients who are likely to develop metastases within five years following surgery.  Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk.  In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.  All MammaPrint tests are conducted in Agendia’s CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments.  Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Irvine, California, and in Amsterdam, the Netherlands.

Media contacts:

Hans Herklots
Agendia
+31.20.462.1557 Office
+31.620.083.509 Mobile
hans.herklots@agendia.com

Todd Aydelotte
Ricochet Public Relations
+1.212.679.3300 x111 Office
todd@ricochetpr.com

Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives

Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows...
January 12, 2023

Gilde Healthcare company Volta medical secures €36M in Series B funding

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding,...
January 5, 2023

Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a...
January 5, 2023